JS Link, Inc. (KOSDAQ:127120)

South Korea flag South Korea · Delayed Price · Currency is KRW
14,070
+230 (1.66%)
Last updated: Jul 14, 2025
339.69%
Market Cap 374.85B
Revenue (ttm) 14.27B
Net Income (ttm) -15.16B
Shares Out 27.08M
EPS (ttm) -723.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 75,004
Average Volume 167,320
Open 13,840
Previous Close 13,840
Day's Range 13,700 - 14,280
52-Week Range 2,750 - 14,450
Beta -0.16
RSI 83.90
Earnings Date Aug 14, 2025

About JS Link

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In additio... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 83
Stock Exchange KOSDAQ
Ticker Symbol 127120
Full Company Profile

Financial Performance

In 2024, JS Link's revenue was 15.91 billion, a decrease of -27.52% compared to the previous year's 21.95 billion. Losses were -10.80 billion, 93.0% more than in 2023.

Financial Statements

News

There is no news available yet.